Abstract

Obesity-associated type 2 diabetes is now recognized as a state of chronic, low-grade metabolic inflammation, 
or metaflammation, driven by adipose tissue immune activation, ectopic lipid deposition, gut dysbiosis, and 
oxidative stress. This inflammatory tone often precedes overt hyperglycemia and structural complications, 
suggesting that early detection of metaflammation could refine risk stratification and enable preventive 
intervention. However, current clinical markers such as fasting glucose, HbA1c and standard lipid panels are 
relatively insensitive to early inflammatory shifts and provide limited spatial or temporal resolution. Emerging 
nanodiagnostic technologies leverage the unique optical, electrical, magnetic and catalytic properties of 
nanomaterials to detect inflammatory biomarkers at ultra-low concentrations in small, minimally invasive 
samples. Metal, carbon, polymeric and hybrid nanostructures can be integrated into biosensors, imaging probes 
and wearable devices to quantify cytokines, adipokines, acute-phase proteins, microRNAs, exosomes and 
oxidative stress products associated with metaflammation in obesity and diabetes. These platforms offer high 
sensitivity, multiplexing capacity and potential for real-time monitoring in blood, interstitial fluid, saliva, sweat 
and breath. This review outlines the biological basis of metaflammation in obesity-associated diabetes, the 
evolving biomarker landscape, and the main classes of nanodiagnostic platforms. It highlights preclinical and 
early translational evidence, discusses technical and regulatory challenges including specificity, standardization 
and nanotoxicology, and explores future directions such as point-of-care multiplex panels, integrated wearables 
and AI-assisted interpretation. By enabling earlier and more precise detection of metaflammation, 
nanodiagnostics may support personalized prevention and more efficient management of obesity-associated 
diabetes.